First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients
To evaluate the efficacy and safety of nab-paclitaxel plus cisplatin plus carilizumab as first-line treatment in patients with metastatic triple-negative breast cancer.
Breast Cancer
DRUG: nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1)
PFS, Progression free survival, 6 weeks|Adverse events, Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0), 6 weeks
To evaluate the efficacy and safety of nab-paclitaxel plus cisplatin plus carilizumab as first-line treatment in patients with metastatic triple-negative breast cancer.